Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global public health emergency. Several vaccine candidates have been developed in response to the COVID-19 pandemic. One approach is to construct live-recombinant viruses expressing the SARS-CoV-2 spike protein (S) as vaccine candidates. The vesicular stomatitis virus (VSV) vector is a mature vaccine platform which was successfully developed as a vaccine against Ebola virus (EBOV), leading to its licensure by the Food and Drug Administration (FDA) in December 2019. Based on this work, we developed two live, replication-competent VSV-vectored vaccines against SARS-CoV-2: (1) a VSV expressing the S protein of SARS-CoV-2 and (2) a bivalent VSV expressing the S protein of SARS-CoV-2 and the glycoprotein (GP) of EBOV. This protocol describes the methodologies for the design, cloning, rescue, and preparation of these recombinant VSV vaccines.
CITATION STYLE
Liu, Q., Ding, Z., Lan, J., & Wong, G. (2022). Design of Replication-Competent VSV- and Ervebo-Vectored Vaccines Against SARS-CoV-2. In Methods in Molecular Biology (Vol. 2410, pp. 193–208). Humana Press Inc. https://doi.org/10.1007/978-1-0716-1884-4_9
Mendeley helps you to discover research relevant for your work.